Trials / Unknown
UnknownNCT06284850
Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels
Red Blood Cell 2,3-biphosphoglycerate Levels in Patients Treated With Empagliflozin. A Prospective Cohort Study.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (estimated)
- Sponsor
- Aristotle University Of Thessaloniki · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to investigate the hypothesis that treatment with empagliflozin may have an impact on red blood cell 2,3-biphosphoglycerate levels affecting tissue oxygen supply and thus mediating part of the cardio- and reno- protective effect of SGLT-2 inhibitors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin10Mg Tab | TB JARDIANCE 10MG |
Timeline
- Start date
- 2023-11-30
- Primary completion
- 2025-11-01
- Completion
- 2025-11-01
- First posted
- 2024-02-29
- Last updated
- 2024-02-29
Locations
1 site across 1 country: Greece
Source: ClinicalTrials.gov record NCT06284850. Inclusion in this directory is not an endorsement.